February 19, 2016 / 3:28 PM / 2 years ago

BUZZ-Valeant Pharmaceuticals: Wells Fargo starts with "underperform"

** Canadian drugmaker's U.S-listed shares down 4.6 pct at $89.79; Toronto-traded stock down 4.4 pct at C$123.77

** Wells Fargo initiates with "underperform" rating and a $65-$68 valuation range, which implies 42 pct downside from the current market value

** "We believe the Valeant board and management have made decisions that may have put Valeant at significant business and reputational risk," analyst David Maris writes in a note

** Analysts, however, remain bullish on the stock with only 1 out of 23 analysts rating it "sell"; 8 have "hold" rating and 14 "buy" or higher

** Median PT $155; stock's intrinsic valuation $191.22, according to StarMine

** Options busy with 13,000 contracts traded in first 30 minutes, 2x the normal pace; trading activity bearish, according to Trade Alert data

** VRX 3/4 weekly 75 put the most active contract; March 50 puts the next most active

** Up to Thursday's close, U.S. stock had fallen 44 pct in 12 months

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below